ArticleLipids in health and disease2025
Evaluation of a new TyG indicator, TyHGB, in predicting non-alcoholic fatty liver disease: evidence from two independent populations.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Association of a new TyG indicator, TyHGB, with cardiovascular disease incidence among the elderly: evidence from a prospective cohort study.BMC geriatrics · 2026Article
- Article
- Association between TyHGB and hyperuricemia and gout in patients with type-2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Association between the triglyceride-high-density lipoprotein-glucose-body index and new-onset stroke risk: a prospective cohort study.Lipids in health and disease · 2026Article
- TyHGB combined with diagonal earlobe crease and traditional risk factors for constructing a diagnostic model of coronary heart disease.Lipids in health and disease · 2026Article
- Systemic immuno-metabolic inflammatory indices (neutrophil-to-HDL cholesterol ratio and systemic inflammation response index) are strongly associated with metabolic dysfunction-associated steatotic liver disease: a propensity score-matched study.Frontiers in immunology · 2026Article
- Association between novel obesity- and lipid-related indices and diabetes across different FBG among elderly: a prospective cohort study.Frontiers in endocrinology · 2026Article
- TyHGB and CVD high-risk stratification: nonlinear association and discrimination in the ChinaHEART Luohe study.Frontiers in endocrinology · 2026Article
- Waist circumference partially mediates the non-linear association between TyHGB and MASLD in non-diabetic Japanese adults.Frontiers in nutrition · 2026Article
- Evaluation of the CHG index for identifying metabolic dysfunction associated steatotic liver disease: evidence from two independent Asian non-obese populations.Frontiers in nutrition · 2026Article
- Article
- The triglyceride-high-density lipoprotein-glucose-body index: a superior novel biomarker for diabetic kidney disease in type 2 diabetes.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAs non-alcoholic fatty liver disease (NAFLD) becomes increasingly common and affects population health, simple and effective screening tools for NAFLD are essential. The triglyceride high-density cholesterol-glucose body index (TyHGB), a novel metabolic index, has shown promise for predicting metabolic disorders. The objective of this research was to assess TyHGB's predictive capability for NAFLD across two distinct cohorts.
methodsThis retrospective study utilized data obtained from two independent cohorts: a Chinese hospital cohort (n = 181,241) and the National Health and Nutrition Examination Survey (NHANES) cohort (n = 3,286). TyHGB was computed according to the following equation: triglyceride level/high-density lipoprotein cholesterol level + 0.7 × fasting blood glucose level (mmol/L) + 0.1 × body mass index (kg/m²). NAFLD was diagnosed using ultrasonography. The TyHGB-NAFLD association was evaluated using multivariable logistic regression analysis, restricted cubic spline methodology, and receiver operating characteristic (ROC) curves. To establish the added predictive capacity of TyHGB over the triglyceride-glucose (TyG) index, net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were determined.
resultsIn both cohorts, participants with higher TyHGB values demonstrated a significantly higher prevalence of NAFLD. After full adjustment for potential confounders, the odds ratios for NAFLD on comparing the highest versus lowest quartiles of TyHGB were 12.22 (95% confidence interval [CI]: 10.73-13.93) in the Chinese cohort and 3.17 (95% CI: 2.25-4.46) in the NHANES cohort. Restricted cubic spline modeling demonstrated significant nonlinear associations between TyHGB values and NAFLD risk in both populations (P for nonlinearity < 0.001). TyHGB demonstrated superior discriminative ability for NAFLD in comparison with the TyG index, with area under the curve (AUC) values of 0.8410 versus 0.7995 in the Chinese cohort and 0.6492 versus 0.5952 in the NHANES cohort (both P < 0.001). Adding TyHGB to the baseline prediction models significantly improved risk discrimination, with greater improvements than those achieved by adding TyG (NRI: 0.0183, 95% CI: 0.015-0.0217; IDI: 0.0067, 95% CI: 0.0057-0.0076; both P < 0.001).
conclusionTyHGB demonstrated robust and superior performance in predicting NAFLD in comparison with the established TyG index across two diverse populations. Since TyHGB only requires routinely measured clinical parameters, it represents a practical and equitable tool for early NAFLD risk stratification across diverse healthcare settings, potentially reducing health disparities in liver disease detection and enabling cost-effective prevention strategies at the population level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.